Synopsis A clinical study demonstrates that nivolumab monotherapy is associated with a substantial and durable tumour response, promising survival, and acceptable safety in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum-based chemotherapy. This week's ' MED FACT ' discusses a clinical trial from , The lancet oncology “ Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial ”. November 2016.
Authors : Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT. Key Takeaways Nivolumab Monotherapy is associated with a substantial and durable clinical response in patients with locally advanced or metastatic urothelial carcinoma. Objective Study Type Participants To study the effect of…
